- THERAPEUTIC COMPOUNDS AND METHODS OF USE
-
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
- -
-
Paragraph 0448; 0449; 0450
(2021/05/21)
-
- Anthracene derivatives compounds and organic electroluminescent devices comprising the same
-
The present invention relates to a novel organic electroluminescent compound which is represented by the following [chemical formula 1] or [chemical formula 2]. The electroluminescent compound according to the present invention has high glass transition temperature, thereby having enhanced thermal stability; and can form an organic electroluminescent device having low driving voltage, high luminance, high color purity, and long-life when applying the same to the electroluminescent device.
- -
-
Paragraph 0157-0162
(2020/07/28)
-
- 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
-
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- -
-
Page/Page column 114
(2010/04/06)
-
- ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
-
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, Ar, m and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- -
-
Page/Page column 34
(2010/02/17)
-
- CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
-
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- -
-
Page/Page column 96
(2010/04/03)
-
- ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
-
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, Q, G, Ar, m, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- -
-
Page/Page column 63
(2010/03/02)
-
- PYRROLIDINE-SUBSTITUTED AZAINDOLE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
-
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, A, B, D, E, G, Ar, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- -
-
Page/Page column 45
(2010/02/17)
-
- 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
-
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- -
-
Page/Page column 131
(2009/04/25)
-
- 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
-
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, R6, B, D, E, G, Q, x and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- -
-
Page/Page column 40
(2009/01/24)
-
- 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
-
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1—R4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- -
-
Page/Page column 62
(2008/12/08)
-
- Indolizines and aza-analog derivatives thereof as CNS active compounds
-
Presently disclosed are indolicine-based compounds of the general formula which have medical utility, for example as antipsychotics.
- -
-
Page/Page column 56-57
(2008/12/08)
-
- Pyrrolo-pyridine kinase modulators
-
The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.
- -
-
Page/Page column 104
(2010/02/15)
-
- NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER
-
The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.
- -
-
Page/Page column 168
(2010/02/12)
-
- Synthesis of arylpiperazines via palladium-catalysed aromatic amination reactions of bromoarenes with N-tert-butoxycarbonylpiperazine
-
Reaction of a series of bicyclic bromoarenes with N-tert- butoxycarbonylpiperazine (N-Boc-piperazine) under palladium-catalysed coupling conditions followed by routine removal of the Boc group with trifluoroacetic acid in dichloromethane gave the corresponding arylpiperazines in moderate to good yield.
- Kerrigan, Frank,Martin, Claire,Thomas, Gerard H.
-
p. 2219 - 2222
(2007/10/03)
-